First Heartland Consultants’s Humacyte HUMA Stock Holding History

First Heartland Consultants’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,925	Closed	-$118K	–	411
2021 Q1	$118K	Buy	+10,925	New	+$119K	0.02%	383

Other funds holding HUMA

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Tudor Investment Corp

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Altium Capital Management New York $42M AUM

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Omni Partners US Irvine, California $1.95B AUM

Arena Capital Advisors Los Angeles, California $200M AUM 23.6% 1-Year Est. Return

First Heartland Consultants's HUMA Position: Q2 2021 in Review

First Heartland Consultants sold out of Humacyte (HUMA) in Q2 2021, closing a stake of 10,925 shares — an estimated $118K sold.

First Heartland Consultants first reported a position in HUMA in Q1 2021 and held it in 1 quarter. The position peaked at $118K in Q1 2021. 28 funds tracked by Wall St. Rank hold HUMA as of Q2 2021.

First Heartland Consultants reported no remaining Humacyte position as of Q2 2021 after selling out during the quarter.
First Heartland Consultants sold 10,925 Humacyte shares in Q2 2021, an estimated $118K.
First Heartland Consultants first reported a position in Humacyte in Q1 2021 and held it in 1 quarter.
First Heartland Consultants's Humacyte position peaked at $118K in Q1 2021.
28 funds tracked by Wall St. Rank held Humacyte as of Q2 2021.

Based on First Heartland Consultants's 13F filing for Q2 2021, filed 16 Aug 2021.